Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Yeztugo
Pharma
NICE rebuffs Gilead's twice-yearly PrEP option
NICE is recommending against national coverage of Gilead Sciences’ landmark twice-a-year PrEP medication lenacapavir.
Fraiser Kansteiner
Sep 10, 2026 10:12am
Gilead crosses FDA finish line with new HIV combo pill
Aug 27, 2026 5:56pm
Gilead's Yeztugo faces growth outlook questions
Aug 5, 2026 10:44am
Gilead, Merck phase 3 data back first weekly HIV pill
Jul 21, 2026 10:00am
ViiV Healthcare launches ‘PrEP Wisdom’ campaign
Jun 1, 2026 9:45am
Gilead says long-acting PrEP Yeztugo in line for $1B in '26 sales
May 8, 2026 11:30am
